CSL Share Price History
03 May, 2021
Seqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age
Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) was as safe and immunogenic as a standard quadrivalent seasonal influenza vaccine (QIV) in children six months through
29 Apr, 2021
Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients
Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension study, simplifies dosage adjustments between two safe and effective doses proven to prevent CIDP relapse - without the need for intravenous immune globulin treatment in the event of a relapse on the low dose. The PATH Extension study was a multicenter, open-label extension study to the Phase III PATH study that evaluated the long-term safety and efficacy of Hizentra 0.2 g/kg and 0.4 g/kg weekly doses in the maintenance treatment of CIDP.
20 Apr, 2021
Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed medical journal Clinical Infectious Diseases.1 Study results indicate aTIV was more effective in reducing influenza-related medical encounters compared with standard egg-based quadrivalent influenza vaccine (QIVe) and high-dose trivalent influenza vaccine (TIV-HD) among adults 65 years and older during the 2017/18 and 2018/19 U.S. influenza seasons.1
19 Apr, 2021
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.
About 12% of Haemonetics 2020 revenue came from a contract with CSL Plasma. CSL declined to renew the accord.
11 Apr, 2021
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
25 Mar, 2021
New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) in peer-reviewed medical journal Vaccines.1 This retrospective cohort analysis indicated QIVc was more effective in reducing hospitalizations/emergency room (ER) visits caused by influenza, respiratory related hospitalizations/ER visits and all-cause hospitalizations compared with an egg-based quadrivalent influenza vaccine (QIVe) among individuals 4–64 years of age during the 2018/19 U.S. influenza season.1
23 Mar, 2021
Health Canada's Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic PartnerMONTREAL, March 23, 2021 /CNW/ -- Seqirus, a world leader in influenza vaccines and pandemic response, announced today that following Health Canada's approval of FOCLIVIA® (adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine), the Company is ready to fulfil its role in Canada's influenza pandemic preparedness plans.Seqirus Canada is an influenza pandemic vaccine partner to the Canadian Government through the Public Health Agency of Canada (PHAC).
18 Mar, 2021
Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older
MONTREAL, March 18, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, announced that Health Canada has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), its cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older. Health Canada previously approved FLUCELVAX QUADRIVALENT for use in persons nine years of age and older.
09 Mar, 2021
In this article, we will take a look at the 15 Most Valuable Australian Companies. You can skip our detailed analysis of Australia’s economy and go to the 5 Most Valuable Australian Companies. Australia proved to be one of the most resilient economies in the wake of the coronavirus crisis. The Australian Bureau of Statistics (ABS) announced […]
05 Mar, 2021
Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older.1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U.S. influenza season.
25 Feb, 2021
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CSL Limited ( ASX:CSL...
26 Jan, 2021
With its stock down 6.4% over the past three months, it is easy to disregard CSL (ASX:CSL). However, a closer look at...
25 Jan, 2021
Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients
Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community support platform, TransplantLyfe, which is dedicated to providing transplant patients, their support partners and donors with the support they need in the transplant journey. Given the relatively low number of individuals undergoing an organ transplant each year, finding others with similar experiences in a local community can be difficult. By providing an active online community, solely focused on transplantation, TransplantLyfe enables connections with others who can relate and provide insights and advice.
12 Jan, 2021
Vaccines from Moderna and the team of Pfizer and BioNTech, in particular, have brought a possible end to the pandemic into sight. The pharma giant Merck (NYSE: MRK) has been especially slow to stir throughout the pandemic.
07 Jan, 2021
Lyfebulb Announces Call-to-Action for Submissions to the 2021 Innovation Challenge: Thriving with Transplantation
Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, unveils the launch of their 2021 Innovation Challenge: Thriving with Transplantation. The goal of this initiative is to source innovative solutions to improve outcomes and experiences for all those affected by organ transplantation.
15 Dec, 2020
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
10 Dec, 2020
CSL Limited Sponsored ADR (CSLLY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
07 Dec, 2020
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced the presentation of new data at the European Scientific Working Group on Influenza (ESWI) virtual conference, demonstrating the immunogenicity and safety of an adjuvanted, cell-based pandemic influenza A (H5N1) vaccine.1,2
Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and meta-analysis presented at the European Scientific Working Group on Influenza (ESWI) virtual conference confirming the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.1 Results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 aTIV was comparable to a high-dose TIV for the same outcome.1